Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04805333 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Dose Escalation of ArtemiCoffee
A Phase 1 study of Ovarian Cancer, sponsored by Frederick R. Ueland, M.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04805333 is a Phase 1 study of Ovarian Cancer that has completed, run by Frederick R. Ueland, M.D.. The registered enrollment target is 13 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04805333, a Phase 1 study of Ovarian Cancer, has completed, sponsored by Frederick R. Ueland, M.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I dose-escalation study of Artemisia annua (Aa) in patients with advanced ovarian cancer who have completed front-line chemotherapy with carboplatin and paclitaxel. The primary objective of this study is to determine the recommended phase II dose (RP2D) of Artemisia annua.
Conditions Studied
Interventions
- DRUG Artemisia annua 450mg
- DRUG Artemisia annua 900mg
- DRUG Artemisia annua 1350mg
- DRUG Artemisia annua 1800mg
- DRUG Artemisia annua - recommended phase II dose
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-03-26 |
| Est. Completion | 2025-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04805333
The ClinicalTrials.gov registry entry for NCT04805333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Frederick R. Ueland, M.D., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Artemisia annua 450mg is the first listed.
NCT04805333 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT04805333 about?
NCT04805333 is a clinical study titled "Phase 1 Dose Escalation of ArtemiCoffee". This is a phase I dose-escalation study of Artemisia annua (Aa) in patients with advanced ovarian cancer who have completed front-line chemotherapy with carboplatin and paclitaxel. The primary objective of this study is to determine the recommended phase II dose (RP2D) of Artemisia annua.
What is the current status of trial NCT04805333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-03-26. Estimated completion is 2025-02-04.
What conditions does trial NCT04805333 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT04805333?
The interventions under investigation include: Artemisia annua 450mg (DRUG), Artemisia annua 900mg (DRUG), Artemisia annua 1350mg (DRUG), Artemisia annua 1800mg (DRUG), Artemisia annua - recommended phase II dose (DRUG).
Who is sponsoring clinical trial NCT04805333?
This trial is sponsored by Frederick R. Ueland, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04805333 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.